Base Technology for Genesis Biopharma’s Contego™ Featured in CNN Report on MD Anderson’s Commitment to Reduce Cancer Deaths

Base Technology for Genesis Biopharma’s Contego™ Featured in CNN Report on MD Anderson’s Commitment to Reduce Cancer Deaths

<0> LHAAnne Marie Fields212-838-3777Senior Vice [email protected]_IR_PR </0>

Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cellular immunotherapies for the treatment of cancer, today announced that cellular immunotherapies for the treatment of cancer was featured in a report by Sanjay Gupta, M.D. in his “Chasing the Cure Series” that first aired on CNN Saturday, September 22 at 4:30 p.m. Eastern time. Dr. Gupta’s report is available at the following link:

The report profiles the University of Texas MD Anderson Cancer Center’s “Giant Leap for Mankind” program with the goal of achieving dramatic declines in mortality over the next five to 10 years, perhaps by up to 50%, for six types of cancer, including melanoma, through better screening, detection and treatment. The report includes a Stage IV melanoma patient who is being treated at MD Anderson with a cellular immunotherapy that, according to Dr. Gupta, involves “taking cells from his immune system, teaching those cells how to fight this specific melanoma, and then putting those cells back into his body, and essentially letting his body, his own immune system, fight that cancer.”

Genesis Biopharma is developing Contego™, a ready-to-infuse adoptive cellular immunotherapy (ACT) using tumor infiltrating lymphocytes (TILs) for the treatment of Stage IV metastatic melanoma. TILs are immune cells which have invaded a patient’s tumor in an attempt to destroy it. Unfortunately, rarely does the patient’s immune system produce enough TILs to destroy the tumor. Dr. Steven Rosenberg, Chief of the Surgery Branch at the National Cancer Institute, developed a process whereby TILs are isolated directly from the patient’s tumor, multiplied to great numbers , and infused into the patient to destroy the patient’s cancer. Contego™ is based on the TIL therapy developed by Dr. Rosenberg for the treatment of patients with Stage IV metastatic melanoma.

“The leading-edge research being conducted at MD Anderson holds potential to benefit cancer patients worldwide, and we are delighted that their work has received heightened visibility on CNN,” stated Anthony J. Cataldo, Chief Executive Officer of Genesis Biopharma. “MD Anderson is one of three U.S. cancer centers working to develop ACT for the treatment of patients with Stage IV melanoma, currently an incurable form of cancer. According to National Cancer Institute estimates, in 2012 there will be more than 76,000 new cases of melanoma in the U.S. and more than 9,000 deaths.”

Genesis Biopharma, Inc. is engaged in the development and commercialization of autologous cell therapies for the treatment of various cancers. The Company’s lead product candidate, Cōntego™, is a ready-to-infuse autologous cellular immunotherapy utilizing tumor infiltrating lymphocytes for the treatment of patients with Stage IV metastatic melanoma.

For more information about the company, visit .

The foregoing announcement contains forward-looking statements that can be identified by such terminology as “expects”, “hopes”, “potential”, “suggests”, “bodes”, “may”, “should”, “could”, or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as of the date they are made. The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.